Mackenzie Financial Corp boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 132.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,531 shares of the biopharmaceutical company's stock after purchasing an additional 19,705 shares during the period. Mackenzie Financial Corp's holdings in Catalyst Pharmaceuticals were worth $721,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in CPRX. Castlekeep Investment Advisors LLC acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at $37,494,000. Bank of America Corp DE grew its holdings in Catalyst Pharmaceuticals by 139.5% during the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock valued at $32,741,000 after purchasing an additional 913,843 shares in the last quarter. abrdn plc acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at $10,115,000. Arrowstreet Capital Limited Partnership grew its holdings in Catalyst Pharmaceuticals by 131.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company's stock valued at $14,570,000 after purchasing an additional 396,506 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after purchasing an additional 390,116 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research analysts have weighed in on the stock. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens reiterated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of "Buy" and an average price target of $32.29.
Read Our Latest Research Report on CPRX
Catalyst Pharmaceuticals Stock Performance
Shares of CPRX stock traded up $0.07 during midday trading on Thursday, reaching $25.36. 929,880 shares of the company were exchanged, compared to its average volume of 1,112,398. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.75 and a 12 month high of $26.16. The company has a market cap of $3.09 billion, a P/E ratio of 21.49, a PEG ratio of 3.31 and a beta of 0.70. The company's 50 day moving average price is $23.60 and its two-hundred day moving average price is $22.71.
Insider Transactions at Catalyst Pharmaceuticals
In other news, insider Gary Ingenito sold 44,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total value of $1,039,720.00. Following the transaction, the insider now owns 68,873 shares of the company's stock, valued at $1,627,468.99. The trade was a 38.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 10.40% of the company's stock.
About Catalyst Pharmaceuticals
(
Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Further Reading
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
